Rheological and anticoagulant therapy of patients with chronic peripheral occlusive arterial disease (COAD). In the course of a six-month study, a three-subgroup cohort of 113 patients (103 m, 10 f, mean age 58 +/- 8 years) with angiographically proven occlusive peripheral arterial disease (COAD) Fontaine stage II was analyzed regarding the therapeutic (improvement of walking performance) and prophylactic (prevention of new vascular events) effects of oral treatment with three different drug regimens. Group A (38 patients) was treated with the anticoagulants phenprocoumon or acenocoumarol group B (32 patients), with the same anticoagulants plus pentoxifylline--800-1200 mg per day